SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody. The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investigator, Professor Johann De Bono at the Royal Marsden Hospital and The Institute of Cancer Research, London. The Phase 1a stage of the trial is currently enrolling multiple solid tumor cancer patients resistant to approved therapies, and is aimed at identifying a recommended Phase 2 dose for further evaluation. "We decided to exercise the
SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody. The Phase 1/2a clinical trial in the United Kingdom is being sponsored and managed by CRUK's Centre for Drug Development and led by Chief Investigator, Professor Johann De Bono at the Royal Marsden Hospital and The Institute of Cancer Research, London. The Phase 1a stage of the trial is currently enrolling multiple solid tumor cancer patients resistant to approved therapies, and is aimed at identifying a recommended Phase 2 dose for further evaluation. "We decided to exercise the
Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK, is partnering with Turbine, a tech-enabled biotech leveraging
Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.
/PRNewswire/ Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced.